Thermo Fisher Scientific announced today that Dr. Park, a South Korean viral‑vector contract development and manufacturing organization, has selected the company to supply advanced bioreactors and consumables for its newest facility. The partnership will equip the facility with state‑of‑the‑art equipment designed for adeno‑associated virus (AAV) production. The move expands Thermo Fisher’s presence in the rapidly growing gene‑therapy manufacturing market.
Dr. Park’s facility is capable of producing 5,000‑liter batches of AAV and can deliver up to 40 clinical‑grade batches per year. The contract underscores Thermo Fisher’s role as a trusted partner for end‑to‑end bioprocessing solutions. It also provides a new revenue stream for the company’s bioproducts and consumables segment.
The agreement highlights Thermo Fisher’s continued investment in the gene‑therapy sector and its strategy to secure high‑volume manufacturing contracts. By supplying critical equipment and consumables, Thermo Fisher strengthens its competitive moat in the life‑sciences market. The deal is expected to contribute to the company’s long‑term growth and reinforce its leadership in bioprocessing technology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.